Chemoradiotherapy Clinical Trial
Official title:
Total Neoadjuvant Treatment Versus Conventional Neo-chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk Factors: a Multicenter Randomized Phase III Clinical Study.
Purpose:To compare the efficacy and the safety of total neoadjuvant chemotherapy + TME with
standard neoadjuvant concurrent chemoradiotherapy + TME + adjuvant chemotherapy for locally
advanced rectal cancer patients with high risk factors of recurrence.
Evaluation indexes: (1) the primary evaluation index: disease-free survival (disease free
survival, DFS); (2) the secondary evaluation indexes: pathological complete remission rate
(pCR), the 3 year overall survival (overall survival, OS); R0 dissection rate; distant
metastasis free survival (DMFS); local recurrence free survival rate (LRRFS); tumor
regression grade (TRG, tumor regression grade) and the adverse reaction rate during the
chemotherapy, the operation safety index; quality of life; psychological and cognitive
effects, assessment of nutritional status.
Safety evaluation indexes: including all adverse events observed during the experiment.
Number of patients: 458 cases Study design: patients will be randomly assigned into the total
neoadjuvant treatment group (experimental group, TNT) and neoadjuvant concurrent chemotherapy
group (control group, CRT) in the ratio of 1: 1. The patients of experimental group will be
given 1 cycle of induction CAPOX (Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2, bid,
d1-14) prior to radiotherapy. Then pelvic IMRT/VMAT (50-50.4Gy/25-28f) and two cycles of
concurrent chemotherapy (Oxaliplatin 130mg/m2, d1, d 22, Capecitabine 825mg/m2, bid, 5d/w,
25-28d) are performed. And three cycles of consolidation chemotherapy (CAPOX) are delivered
after concurrent chemoradiotherapy. Total mesorectal excision (TME) is performed after
completion of the whole neoadjuvant treatment. The patients of control group will receive
standard concurrent neoadjuvant chemoradiotherapy with capecitabine (825mg/m2, bid, 5d/w)
followed by TME 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients are
treated with another 6 cycles of CAPOX.
Schedule: Investigators plan to finish the study in 4 years and write the related work within
2 years after the completion of this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Completed |
NCT02399306 -
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
|
Phase 3 | |
| Recruiting |
NCT03286348 -
Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer
|
N/A | |
| Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT04278287 -
Chemoradiotherapy in Unresectable Esophageal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05863260 -
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
|
||
| Active, not recruiting |
NCT05027165 -
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
|
||
| Completed |
NCT04207918 -
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT06219083 -
Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy
|
||
| Active, not recruiting |
NCT04764227 -
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
|
Phase 2 | |
| Recruiting |
NCT06421376 -
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05286086 -
Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative
|
N/A | |
| Recruiting |
NCT04772001 -
Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer
|
N/A | |
| Recruiting |
NCT06429839 -
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT06410651 -
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06413342 -
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT05590650 -
A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients
|
Phase 1 | |
| Recruiting |
NCT00973778 -
A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06190847 -
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
|